Traws Pharma (TRAW) Q4 2024 & Study Update earnings summary

Executive summary

• Presented two antiviral candidates: tivoxavir marboxil for bird flu and ratutrelvir for COVID, both showing best-in-class potential and broad resistance profiles.

• Tivoxavir marboxil demonstrated potent efficacy in preclinical models and favorable pharmacokinetics, supporting single-dose therapy for treatment and prophylaxis.

• Ratutrelvir offers a ritonavir-independent regimen, addressing limitations of current COVID antivirals and enabling use in high-risk populations.

• Refocused on respiratory viral diseases, prioritizing bird flu with lead candidate tivoxavir marboxil; positive preclinical and Phase 1 data support accelerated FDA pathway discussions.

• CEO transition announced: Werner Cautreels retiring, Iain D. Dukes appointed Interim CEO.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $21.3 million at year-end 2024, up from $20.8 million in 2023.

• Net loss for 2024 was $166.5 million, primarily due to $117.5 million acquired in-process R&D and $24.4 million warrant expense; net loss per share was $35.21.

• R&D expenses increased to $12.8 million (from $11.4 million in 2023), mainly for clinical/preclinical trials and personnel.

• G&A expenses rose to $12.3 million (from $9.1 million), driven by consulting fees for strategic alternatives.

• 5,073,790 shares outstanding as of March 26, 2025, reflecting 3.9 million new shares from December financing.

Outlook and guidance

• Cash runway expected to support operations into Q1 2026.

• Expecting FDA feedback on Animal Rule for bird flu in Q2 2025.

• Finalizing formulations, CMC scale-up, and development for bird flu, with a path to approval underway.

• For COVID, a pre-IND meeting request will be submitted to discuss milestones and endpoints for Long COVID.

• COVID: Pre-IND meeting request to FDA for long COVID endpoints planned for Q2 2025.